toll-like receptor

  1. cassava7

    2022: a banner year for systematic lupus erythematosus?, Lancet Rheumatology editorial

    2022 has been an auspicious year for systemic lupus erythematosus (SLE). In February, the interferon receptor inhibitor anifrolumab became only the second targeted agent to be approved in Europe for treatment of SLE in more than six decades. A few months later, a 7-year-old Spanish girl who...
  2. Andy

    Animal Models for Neuroinflammation and Potential Treatment Methods, 2022, Tamura et al

    [This seems to be only very tenuously about ME/CFS] Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating chronic disease of unknown etiology and without effective treatment options. The onset of ME/CFS is often associated with neuroinflammation following bacterial or...
    • Andy
    • Thread
    • animal model il-1b il-1ß minocycline neuroinflammation treatment
    • Replies: 4
    • Forum: ME/CFS research
  3. Andy

    TLR7 gain-of-function genetic variation causes human lupus, 2022, Brown et al

    Abstract Although circumstantial evidence supports enhanced Toll-like receptor 7 (TLR7) signalling as a mechanism of human systemic autoimmune disease1,2,3,4,5,6,7, evidence of lupus-causing TLR7 gene variants is lacking. Here we describe human systemic lupus erythematosus caused by a TLR7...
  4. Dolphin

    The Role of EBV-dUTPase in Modulating Neuro-Immune Dysfunction Associated with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, 2020, Hasik

    Free full text: https://kb.osu.edu/bitstream/handle/1811/91637/julia_hasik_thesis_20200424.pdf?sequence=1&isAllowed=y
    • Dolphin
    • Thread
    • 2020 antibodies dutpase ebv hasik herpesvirus il-1ß me/cfs paper
    • Replies: 0
    • Forum: ME/CFS research
Back
Top Bottom